Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase Context Sensitive Links 1 of 2 Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F71009396%3A_____%2F22%3AN0000010" target="_blank" >RIV/71009396:_____/22:N0000010 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.sciencedirect.com/science/article/pii/S0928098722001373?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0928098722001373?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejps.2022.106252" target="_blank" >10.1016/j.ejps.2022.106252</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase Context Sensitive Links 1 of 2 Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase
Popis výsledku v původním jazyce
Novel antimycobacterial drugs are needed, especially those with dual activity against both actively growing and non-replicating subpopulations of mycobacteria. Isocitrate lyase (ICL) is one of proposed targets and this enzyme is inhibited by itaconic acid. That is why we have designed and prepared sixteen amides of itaconic acid and various anilines and amine antimicrobial drugs to evaluate them as potential inhibitors of ICL and antimycobacterial agents. N-Phenylitaconamides were prepared from itaconic anhydride and substituted anilines (yields 57-99%). They were characterized and evaluated against mycobacterial ICL and against actively growing mycobacteria (M. tuberculosis H37Rv, M. avium, two strains of M. kansasii). All derivatives showed antimycobacterial efficacy with minimum inhibitory concentrations starting from 125 mu M. M. kansasii was the most susceptible species. Itaconamides derived from sulfonamides or p-aminosalicylic acid were optimal for activity against extracellular mycobacteria. ICL1 was significantly inhibited by two compounds, with 2-methylene-4-[(4nitrophenyl)amino]-4-oxobutanoic acid 1k being the most potent (36% inhibition at 10 mu M), which was also more efficient than two comparators. Molecular docking revealed its mode of binding to the enzyme. Using in silico tools, physicochemical properties and structural features for drug-likeness and gastrointestinal absorption were evaluated.
Název v anglickém jazyce
Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase Context Sensitive Links 1 of 2 Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase
Popis výsledku anglicky
Novel antimycobacterial drugs are needed, especially those with dual activity against both actively growing and non-replicating subpopulations of mycobacteria. Isocitrate lyase (ICL) is one of proposed targets and this enzyme is inhibited by itaconic acid. That is why we have designed and prepared sixteen amides of itaconic acid and various anilines and amine antimicrobial drugs to evaluate them as potential inhibitors of ICL and antimycobacterial agents. N-Phenylitaconamides were prepared from itaconic anhydride and substituted anilines (yields 57-99%). They were characterized and evaluated against mycobacterial ICL and against actively growing mycobacteria (M. tuberculosis H37Rv, M. avium, two strains of M. kansasii). All derivatives showed antimycobacterial efficacy with minimum inhibitory concentrations starting from 125 mu M. M. kansasii was the most susceptible species. Itaconamides derived from sulfonamides or p-aminosalicylic acid were optimal for activity against extracellular mycobacteria. ICL1 was significantly inhibited by two compounds, with 2-methylene-4-[(4nitrophenyl)amino]-4-oxobutanoic acid 1k being the most potent (36% inhibition at 10 mu M), which was also more efficient than two comparators. Molecular docking revealed its mode of binding to the enzyme. Using in silico tools, physicochemical properties and structural features for drug-likeness and gastrointestinal absorption were evaluated.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
<a href="/cs/project/GJ20-19638Y" target="_blank" >GJ20-19638Y: Design a studium nových antimikrobních látek účinných na rezistentní a biofilm-produkující gram-pozitivní bakterie</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
European Journal of Pharmaceutical Sciences
ISSN
0928-0987
e-ISSN
1879-0720
Svazek periodika
176
Číslo periodika v rámci svazku
106252
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
8
Strana od-do
1-8
Kód UT WoS článku
000839196000010
EID výsledku v databázi Scopus
2-s2.0-85134358236